doctor shaking hands with pharmaceutical rep

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Share Post:

Strengthen Your Customer Connections

Understanding the world prescribers are living in allows for more meaningful customer interactions. MAP Training Programs build your knowledge on marketplace trends impacting providers and the pharmaceutical industry today. 

Begin learning today

Achieve Company Goals

Bring teams up-to-speed on the latest market access trends impacting their unique selling environment.

View custom training solutions

Keep Your Finger on The Pulse

Subscribe to the Marketplace Blog to stay up-to-date on the latest trends impacting pharma

*required





    Privacy Guaranteed — We will never share your info

    Marketplace Blog

    Trends in the Marketplace

    Fractures in The 340B Program

    The 340B Program remains controversial. Hospitals and other Covered Entities (providers qualified to buy drugs at 340B prices) that benefit from the program describe it as a lifeline that keeps

    The Impact of Medicare Price Negotiations

    The Inflation Reduction Act (IRA) passed on August 16th, 2022 brings big changes for the pharmaceutical industry. On August 31st we had a live discussion on the law’s anticipated impact.

    The Business of Medicine

    The Shifting of Risk in the Market Access Environment

    The patient’s needs will always come first. More and more often, however, healthcare providers are forced to make their clinical decisions in a business environment. Though that environment is not always ideal, patients cannot be treated if the medical practice or hospital cannot operate as a viable business. ProFusion specializes in helping your learners understand how business pressures impact the point where clinical decisions are made. By establishing learning objectives that build a broad and deep understanding of the business of medicine, ProFusion can help you understand:

    • How insurers, healthcare providers, and purchasers (i.e. employers and individuals) share financial risk for the cost of healthcare
    • How even patients are assuming more risk (i.e. through high deductible plans and making the purchase decisions on Health Insurance Exchanges)
    • How this risk impacts the decisions made by all these stakeholders
    • How stakeholder decisions impact product access (healthcare services delivered and drugs prescribed)
     

    Manufacturers Restricting 340B Sales to Contract Pharmacies

    • Abbvie
    • Amgen
    • AstraZeneca
    • Boehringer Ingelheim
    • Eli Lilly
    • Merck
    • Novartis
    • Novo Nordisk
    • Sanofi
    • UCB
    • United Therapeutics
    • and more…